Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 771

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 3
Chunk 771
---
700 19,550 Operating lease liabilities, non-current 14,914 31,606 Convertible senior notes, net, non-current647,494 892,243 Other liabilities, non-current 546 751 Total liabilities 753,853 1,044,709 Commitments and contingencies Stockholders’ equityPreferred stock, $0.001 par value:Authorized 50,000 shares; No shares issued or outstanding — — Common stock, $0.001 par value:Authorized 1,000,000 shares; issued and outstanding 294,418 and 267,744 shares at December 31, 2024 and December 31, 2023, respectively 294 268 Additional paid-in capital 2,654,804 2,539,892 Accumulated other comprehensive income422 219 Accumulated deficit (2,148,926)(1,839,075)Total stockholders’ equity 506,594 701,304 Total liabilities and stockholders’ equity $1,260,447 $1,746,013 

See accompanying notes to the consolidated financial statements. 

Fiscal 2024 Form 10-K85

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Years Ended December 31,(in thousands, except per share amounts)202420232022Revenue:Product revenue $136,149 $183,872 $108,699 Service and other revenue 17,865 16,649 19,605 Total revenue 154,014 200,521 128,304 Cost of Revenue:Cost of product revenue 92,284 127,568 60,932 Cost of service and other revenue 14,057 14,754 13,899 Amortization of acquired intangible assets9,393 1,983 733 Loss on purchase commitment998 3,436 3,705 Total cost of revenue 116,732 147,741 79,269 Gross profit 37,282 52,780 49,035 Operating Expense:Research and development 134,922 187,170 193,000 Sales, general and administrative 175,017 169,818 160,854 Impairment charges184,500 — — Merger-related expenses— 9,